ArticleProceedings of the National Academy of Sciences of the United States of America2026
A ligandable PNT domain establishes ERG as a directly targetable oncogenic driver in prostate cancer.
Erratum issuedAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A ligandable PNT domain establishes ERG as a directly targetable oncogenic driver in prostate cancer.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
32 authors.
Xiaoju Wang *Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.
Wenyan Liu *Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.
Jiehao Yang *State Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, People's Republic of China.
Jean Ching-Yi TienMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.ORCID 0000-0002-2684-4450
Yu ChangMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.
Rahul MannanMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.ORCID 0000-0002-6642-0468
Somnath MahapatraMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.
Yang ZhouInternational Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education, Guangzhou City Key Laboratory of Precision Chemical Drug Development, College of Pharmacy, Jinan University, Guangzhou 511400, People's Republic of China.
Lihao GanState Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, People's Republic of China.
Xuhong CaoMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.
Jiayi ZhouMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.
Yuping ZhangMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.ORCID 0000-0002-8727-5183
Sharpkate ShakerMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.
Yichao HuangState Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, People's Republic of China.
Hang QiaoState Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, People's Republic of China.
Rudana HamadehMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.
Grafton ErvineMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.
Cynthia WangMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.
Fengyun SuMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.
Rui WangMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.ORCID 0000-0002-5356-9685
Lanbo XiaoMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.
Raghunath Ranga SudharshanDepartment of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI 48109.
Arvind RaoMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.
Zaneta Nikolovska-ColeskaDepartment of Pathology, University of Michigan, Ann Arbor, MI 48109.
Cole StephensMedicinal Chemistry Graduate Program, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109.ORCID 0009-0002-5150-3401
Lifeng PanState Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, People's Republic of China.ORCID 0000-0002-9229-6288
James J ChouState Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, People's Republic of China.
Debashish SahuBioNMR Core Facility, Life Sciences Institute, University of Michigan, Ann Arbor, MI 48109.
Jeanne StuckeyRogel Cancer Center, University of Michigan, Ann Arbor, MI 48109.
Zhen WangState Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, People's Republic of China.ORCID 0000-0001-8762-6089
Ke DingState Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, People's Republic of China.ORCID 0000-0001-9016-812X
Arul M ChinnaiyanMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.ORCID 0000-0001-9282-3415
Funding
Tissue/InformaticsP50CA186786 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Ganesh S Palapattu · 2014 to 2026
$27.6MExploring Precision Oncology: From Gene Fusions to lncRNAsR35CA231996 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHINNAIYAN, ARUL M · 2018 to 2024
$6.4MMichigan-VUMC Biomarker Characterization CenterU2CCA271854 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jeffrey John Tosoian · 2022 to 2026
$5.4MHHMI (HHMI) N/AHHS | NIH | National Cancer Institute (NCI) 2P50CA186786-11A1HHS | NIH | National Cancer Institute (NCI) R35-CA231996HHS | NIH | National Cancer Institute (NCI) U2C-CA271854Natural Science Foundation of China 22521104NCI NIH HHS P50 CA186786NCI NIH HHS R35 CA231996NCI NIH HHS U2C CA271854Prostate Cancer Foundation (PCF) N/AStrategic Priority Research Program of the Chinese Academy of Sciences XDB1060000
Abstract
The
Indexed as
Prostatic NeoplasmsTranscriptional Regulator ERGAnimalsCell Line, TumorCell ProliferationHumansLigandsMaleMiceMolecular Docking SimulationOncogene Proteins, FusionProtein DomainsXenograft Model Antitumor AssaysERG protein, humanLigandsOncogene Proteins, FusionTranscriptional Regulator ERGERG transcription factorgene fusionPNT domainprostate cancersmall-molecule inhibitor
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.